The Indian government is set to unveil a comprehensive new law designed to strengthen regulatory oversight and elevate quality standards for drugs, medical devices, and cosmetics nationwide. This move comes in response to mounting concerns about the safety and effectiveness of products in these critical sectors, aiming to establish a modern framework for monitoring, testing, and enforcement.
Officials indicate that the new legislation will replace the outdated Drugs and Cosmetics Act of 1940, bridging regulatory gaps that have become apparent with ongoing scientific and technological advancements. Central features of the new law include stringent quality control measures, heightened post-market surveillance, and robust protocols for product recalls and penalties for non-compliance. Notably, medical devices will be regulated as a separate category under the new act, helping bring clarity and focus to their oversight.
The proposed bill mandates rigorous quality assurance practices for manufacturers and importers, requires regular audits, enforces mandatory adverse event reporting, and grants enhanced authority to regulators for prompt corrective action in the event of violations. The legislation also seeks to align domestic standards with international best practices, positioning India more competitively as a global supplier of pharmaceuticals and medical devices.
Industry stakeholders have expressed support for the proposed changes, emphasizing that a transparent and predictable regulatory environment will enhance patient safety and encourage continued innovation. The draft bill will be circulated among state governments and related industry groups for feedback and consultation in the near future.
With this planned legislation, the government aims to reinforce public health protections and consumer safety, as India’s role in the global healthcare supply chain expands and domestic demand for high-quality medicines and devices continues to grow.
